Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Cortexyme Inc (NQ: CRTX )

3.300 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EDT, May 19, 2022 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 0
Open 3.300
Bid (Size) 3.310 (4)
Ask (Size) 3.580 (5)
Prev. Close 3.300
Today's Range 3.300 - 3.300
52wk Range 3.000 - 121.98
Shares Outstanding 30,150,835
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News
Cortexyme to Participate at 4th International Conference on Porphyromonas gingivalis and Related Species in Oral and Systemic Diseases
From Cortexyme, Inc.
Via Business Wire
77 Stocks Moving In Tuesday's Mid-Day Session
Gainers 
Via Benzinga

Performance

YTD
-75.35%
-75.35%
1 Month
-23.61%
-23.61%
3 Month
-30.23%
-30.23%
6 Month
-74.42%
-74.42%
1 Year
-91.21%
-91.21%

More News

Read More
Cortexyme Announces Further Layoffs, Chief Medical Officer Leaves
Via Benzinga
103 Biggest Movers From Yesterday
Via Benzinga
The Daily Biotech Pulse: Pfizer Acquires Migraine Drugmaker For $11B, Biogen Files For Second Alzheimer's Drug Approval, Longeveron CEO Leaves
Via Benzinga
Cortexyme Announces Agreement to Acquire Novosteo
From Cortexyme, Inc.
Via Business Wire
The Daily Biotech Pulse: FDA's AdComm For Acadia's Pimavanserin, Review Issues For Spero's Tebipenem Application, Cortexyme Layoffs
Via Benzinga
NASDAQ:CRTX Investor Alert: Investigation over Potential Wrongdoing at Cortexyme, Inc.
Via SBWire
ROSEN, RESPECTED INVESTOR COUNSEL, Encourages Cortexyme, Inc. Investors With Losses to Inquire About Securities Class Action Investigation – CRTX
From The Rosen Law Firm, P.A.
Via Business Wire
Cortexyme Provides New GAIN Trial Data at AD/PD 2022 Demonstrating Potential Benefit of Lysine Gingipain Inhibition in Mild to Moderate Alzheimer’s Population
From Cortexyme, Inc.
Via Business Wire
Short-Squeeze Stocks: Top 10 Stocks With High Short Interest Today
Via InvestorPlace
Cortexyme Appoints Marwan Sabbagh, MD, to its Board of Directors
From Cortexyme, Inc.
Via Business Wire
Cortexyme to Present New GAIN Trial Data at AD/PD 2022
From Cortexyme, Inc.
Via Business Wire
10 Biggest Price Target Changes For Wednesday
Via Benzinga
Cortexyme Posts Safety Data From SAD Portion Of COR588 Trial In P.Gingivalis
Via Benzinga
CORTEXYME ALERT: Bragar Eagel & Squire, P.C. is Investigating Cortexyme, Inc. on Behalf of Cortexyme Stockholders and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire, P.C.
Via Business Wire
NASDAQ:CRTX Shareholder Notice: Investigation over Potential Securities Laws Violations by Cortexyme, Inc.
Via SBWire
CORTEXYME ALERT: Bragar Eagel & Squire, P.C. Is Investigating Cortexyme, Inc. on Behalf of Cortexyme Stockholders and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via Business Wire
Investigation Notice: The Schall Law Firm Encourages Investors in Cortexyme, Inc. with Losses of $100,000 to Contact the Firm
Via NewMediaWire
Investigation Alert: The Schall Law Firm Encourages Investors in Cortexyme, Inc. with Losses of $100,000 to Contact the Firm
Via NewMediaWire
Ongoing Investigation Reminder: The Schall Law Firm Encourages Investors in Cortexyme, Inc. with Losses of $100,000 to Contact the Firm
Via NewMediaWire
Stocks That Hit 52-Week Lows On Thursday
Via Benzinga
INVESTIGATION REMINDER: The Schall Law Firm Encourages Investors in Cortexyme, Inc. with Losses of $100,000 to Contact the Firm
From The Schall Law Firm
Via Business Wire
INVESTIGATION ALERT: The Schall Law Firm Encourages Investors in Cortexyme, Inc. with Losses of $100,000 to Contact the Firm
From The Schall Law Firm
Via Business Wire
EQUITY ALERT: ROSEN, A TOP RANKED LAW FIRM, Encourages Cortexyme, Inc. Investors with Losses in Excess of $100K to Inquire About Securities Class Action Investigation – CRTX
From Rosen Law Firm
Via Business Wire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.